Increlex®
mecasermin
Description
Increlex® is a liquid formulation of recombinant human insulin-like growth factor-1(IGF-1).
Active substance
mecasermin, recombinant DNA-derived human IGF-1, Escherichia coli
Indications
Increlex® is indicated for:
the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (primary IGFD).
Severe primary IGFD is defined by:
- Height standard deviation score ≤ -3.0 and
- Basal IGF-1 levels below the 2.5th percentile for age and gender and
- GH sufficiency
- Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.
Severe primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. It is recommended to confirm the diagnosis by conducting an IGF-1 generation test.
